From Molecular Insights to Clinical Strategies: Delve into the complexities of cachexia, encompassing cancer cachexia, molecular mechanisms, and evolving therapeutic approaches. Discover the forefront of research aimed at understanding and combating this debilitating condition.
Alzheimer's disease (AD) impairs cognitive functions and peripheral systems, including skeletal muscles. The PS19 mouse, expressing the human tau P301S mutation, shows cognitive and muscular pathologies, reflecting the central and peripheral atrophy seen in AD. We analysed skeletal muscle morphology...
🗓️ 2024-04-22
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Lean body mass (LBM) and the functional capacity of cardiovascular (CV) and respiratory systems constitute a female-specific relationship in European-American individuals. Whether this recent finding be extrapolated to the world's largest ethnic group, that is, Hans Chinese (HC, a population...
🗓️ 2024-04-17
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Body weight and its changes have been associated with cancer outcomes. However, the associations of short-term peridiagnosis weight dynamics in standardized, clinically operational time frames with cancer survival remain largely unknown. This study aimed to screen for and evaluate the...
🗓️ 2024-04-21
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Muscle atrophy can cause muscle dysfunction and weakness. Krüppel-like factor 13 (KLF13), a central regulator of cellular energy metabolism, is highly expressed in skeletal muscles and implicated in the pathogenesis of several diseases. This study investigated the role of KLF13...
🗓️ 2024-07-08
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Low skeletal muscle mass (LSMM) and/or, function associated with an increased risk of treatment-related toxicities and inferior overall survival (OS) among adults with solid malignancies. However, the association between LSMM and treatment-related toxicities among adults with haematologic malignancies remains unclear....
🗓️ 2024-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Loss of muscle strength and endurance with aging or in various conditions negatively affects quality of life. Resistance exercise training (RET) is the most powerful means to improve muscle mass and strength, but it does not generally lead to improvements...
🗓️ 2024-06-16
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Sarcopenia and low areal bone mineral density (aBMD) are prevalent musculoskeletal complications after paediatric cancer treatment. However, their relationship has not been examined in young paediatric cancers survivors. This study aimed to evaluate aBMD differences according to sarcopenia status and...
🗓️ 2024-08-20
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Glycative stress, characterized by the formation and accumulation of advanced glycation end products (AGEs) associated with protein glycation reactions, has been implicated in inducing a decline of muscle function. Although the inverse correlation between glycative stress and muscle mass and...
🗓️ 2024-04-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Hydrogen sulfide (HS), the third gasotransmitter discovered, regulates a variety of physiological functions. Whether HS alleviates skeletal muscle ageing by regulating autophagy has not been reported. Mice were administered 150 mg/kg/day of D-galactose ( D-gal), and C2C12 myotubes were cultured in...
🗓️ 2024-08-27
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
In the context of cardiovascular surgery, the foremost concern lies in delayed functional recovery, as typified by the acquisition of independent walking after surgery, among older patients with decline in skeletal muscle mass and quality. Computed tomography (CT), which is...
🗓️ 2024-06-19
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
The CTNS gene mutation causes infantile nephropathic cystinosis (INC). Patients with INC develop Fanconi syndrome and chronic kidney disease (CKD) with significant bone deformations. C57BL/6 Ctns mice are an animal model for studying INC. Hyperleptinaemia results from the kidney's inability...
🗓️ 2024-08-29
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Excess muscle fat is observed in obesity and associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat and adverse muscle composition is...
🗓️ 2024-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Sarcopenia has been associated with adverse health outcomes, including cognitive dysfunction. However, its specific interrelationship with neurocognitive disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD) or other types of dementia has not been thoroughly explored. This meta-analysis aims...
🗓️ 2024-05-07
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Accurate preoperative risk assessment for major colorectal cancer (CRC) surgery remains challenging. Body composition (BC) and cardiopulmonary exercise testing (CPET) can be used to evaluate risk. The relationship between BC and CPET in patients undergoing curative CRC surgery is unclear....
🗓️ 2024-06-26
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Telomere attrition may share common biological mechanisms with bone and muscle loss with aging. Here, we investigated the association between these hallmarks of aging using data from UK Biobank, a large observational study. Leukocyte telomere length (LTL as T/S ratio)...
🗓️ 2024-03-29
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Regaining walking ability is a key target in geriatric rehabilitation. This study evaluated the prevalence of walking ability at (pre-)admission and related clinical characteristics in a cohort of geriatric rehabilitation inpatients; in inpatients without walking ability, feasibility and effectiveness of...
🗓️ 2024-09-05
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Cachexia has been defined as a loss of lean tissue mass, involving a weight loss greater than 5% of body weight in 12 months or less in the presence of chronic illness or as a body mass index (BMI) lower than 20 kg/m2. In addition, usually three of the following five criteria are required: decreased muscle strength, fatigue, anorexia, low fat-free mass index, increase of inflammation markers such as C-reactive protein or interleukin (IL)-6 as well as anaemia or low serum albumin.
Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke.
REFERENCES
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793–799
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
Subscribe to the SCWD Newsletter
Stay Informed with the Latest Updates and Exclusive Insights!